Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

SAGETRACK
Journal of the Society for Gynecologic Investigation
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Hirtenlehner, K.
Right arrow Articles by Knöfler, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hirtenlehner, K.
Right arrow Articles by Pollheimer, J.
Right arrow Articles by Lichtenberger, C.
Right arrow Articles by Wolschek, M. F.
Right arrow Articles by Zeisler, H.
Right arrow Articles by Husslein, P.
Right arrow Articles by Knöfler, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Elevated Serum Concentrations of the Angiogenesis Inhibitor Endostatin in Preeclamptic Women

Kora Hirtenlehner, MD

Jürgen Pollheimer

Cornelia Lichtenberger

Markus F. Wolschek, PhD

Harald Zeisler, MD

Peter Husslein, MD

Departments of Obstetrics and Gynecology and Internal Medicine IV, University of Vienna, Vienna, Austria

Martin Knöfler, PhD

Departments of Obstetrics and Gynecology and Internal Medicine IV, University of Vienna, Vienna, Austria; Department of Obstetrics and Gynecology, University of Vienna, AKH, Waehringer Guertel 18-20, A-1090 Vienna, Austria martin.knoefler{at}akh-wien.ac.at

Objective: Changes in serum levels of angiogenic factors such as vascular endothelial growth factor or placental growth factor were associated with preeclampsia. The aim of our study was to investigate the concentrations of endostatin, a potent endogenous inhibitor of angiogenesis and endothelial or tumor cell growth, in preeclamptic patients.

Methods: Levels of soluble endostatin were determined by enzyme-linked immunosorbent assay and Western blot analysis in sera of nonpregnant women, healthy pregnant women, and patients with different forms of preeclampsia.

Results: Statistical analyses of age-matched study groups revealed elevated medians of endostatin concentration for severely (30.5 ng/mL) and mildly (26.05 ng/mL) preeclamptic patients compared with healthy pregnant (17.2 ng/mL) and nonpregnant women (17.2 ng/mL). Western blot analysis confirmed the up-regulation of soluble endostatin molecules (24 kD) in sera of severely preeclamptic patients.

Conclusion: Elevated concentrations of endostatin could play a role in the pathophysiology of preeclampsia by counteracting the effects of vascular endothelial growth factor. The inhibitor could also be responsible for the observed growth-inhibitory effects of preeclamptic plasma on endothelial cells.

Key Words: Endostatin • preeclampsia • serum • angiogenesis

Journal of the Society for Gynecologic Investigation, Vol. 10, No. 7, 412-417 (2003)
DOI: 10.1016/S1071-55760300142-4
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?